当前位置： SCI文献检索 > VACCINE期刊下所有文献 > The Meningitis Vaccine Project.

The Meningitis Vaccine Project.

Abstract：

:Epidemic meningococcal meningitis is an important public health problem in sub-Saharan Africa. Current control measures rely on reactive immunizations with polysaccharide (PS) vaccines that do not induce herd immunity and are of limited effectiveness in those under 2 years of age. Conversely, polysaccharide conjugate vaccines are effective in infants and have consistently shown an important effect on decreasing carriage, two characteristics that facilitate disease control. In 2001 the Meningitis Vaccine Project (MVP) was created as a partnership between PATH and the World Health Organization (WHO) with the goal of eliminating meningococcal epidemics in Africa through the development, licensure, introduction, and widespread use of conjugate meningococcal vaccines. Since group A Neisseria meningitidis (N. meningitidis) is the dominant pathogen causing epidemic meningitis in Africa MVP is developing an affordable (US$ 0.40 per dose) meningococcal A (Men A) conjugate vaccine through an innovative international partnership that saw transfer of a conjugation and fermentation technology to a developing country vaccine manufacturer. A Phase 1 study of the vaccine in India has shown that the product is safe and immunogenic. Phase 2 studies have begun in Africa, and a large demonstration study of the conjugate vaccine is envisioned for 2008-2009. After extensive consultations with African public health officials a vaccine introduction plan has been developed that includes introduction of the Men A conjugate vaccine into standard Expanded Programme on Immunization (EPI) schedules but also emphasizes mass vaccination of 1-29 years old to induce herd immunity, a strategy that has been shown to be highly effective when the meningococcal C (Men C) conjugate vaccine was introduced in several European countries. The MVP model is a clear example of the usefulness of a "push mechanism" to finance the development of a needed vaccine for the developing world.

journal_name

Vaccine

journal_title

Vaccine

authors

LaForce FM,Konde K,Viviani S,Préziosi MP

doi

10.1016/j.vaccine.2007.04.049

subject

Has Abstract

pub_date

2007-09-03 00:00:00

pages

A97-100

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(07)00474-4

journal_volume

25 Suppl 1

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Primary in vitro sensitization of human T-helper lymphocytes by peptides derived from the V3 loop of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein.

    abstract：:To generate CD4+ T-helper cell lines, lymphocytes from HIV-seronegative subjects were primed in vitro with peptides derived from the V3 loop of HIV-1 gp120. Antigen-specific reactivity was inhibited by an anti-DR monoclonal antibody, indicating HLA-class II dependency, but peptides could be recognized in different HLA...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(94)90010-8

    authors： Billaud JN,Yagello M,Gluckman JC

    更新日期：1994-01-01 00:00:00

  • Polio Eradication Initiative: Contribution to improved communicable diseases surveillance in WHO African region.

    abstract：INTRODUCTION:Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988, there has been a tremendous progress in the reduction of cases of poliomyelitis. The world is on the verge of achieving global polio eradication and in May 2013, the 66th World Health Assembly endorsed the Polio Eradication and End...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.05.060

    authors： Mwengee W,Okeibunor J,Poy A,Shaba K,Mbulu Kinuani L,Minkoulou E,Yahaya A,Gaturuku P,Landoh DE,Nsubuga P,Salla M,Mihigo R,Mkanda P

    更新日期：2016-10-10 00:00:00

  • Testing for AIDS on samples of dried blood prepared on filter papers.

    abstract：:A substantial rise in the number of AIDS cases has been observed during the past year in many African countries, and HIV-2 indigenous transmission and increased disease have since gained importance in Senegal. Both for HIV-1 and HIV-2 diagnosis, ELISA positivity is followed by a Western blot test for specific antibodi...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(88)90210-1

    authors： Arya SC

    更新日期：1988-06-01 00:00:00

  • Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120.

    abstract：:Amino acid residues 421-436 constitute a comparatively conserved determinant of gp120 that participates in the binding of host cell CD4 receptors by HIV-1. We compared the immunogenicity of synthetic Cys-gp120 (421-436) conjugated to KLH via the N terminal Cys residue (KLH-I) and gp120 (421-436) extended at its N term...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(02)00504-2

    authors： Karle S,Nishiyama Y,Taguchi H,Zhou YX,Luo J,Planque S,Hanson C,Paul S

    更新日期：2003-03-07 00:00:00

  • Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.

    abstract：:The ability to elicit humoral and cell-mediated immune (CMI) responses from DNA immunization by combinational use of codon optimization and C3d component of complement was evaluated in this study. DNA vaccines that express either the wild type or the codon optimized gp120 gene coding for the envelope (Env) glycoprotei...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2003.09.054

    authors： Liu F,Mboudjeka I,Shen S,Chou TH,Wang S,Ross TM,Lu S

    更新日期：2004-04-16 00:00:00

  • Awareness campaigns: experience in Mexico.

    abstract：:The current total of AIDS cases in Mexico is 37,000 of which 86% have occurred in men. The major route of transmission is sexual. The campaign to prevent AIDS has fallen into four phases, and has now been extended to other sexually transmitted diseases, including hepatitis B. The first phase (1985-1989) was based arou...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(99)00475-2

    authors： Hernández Tepichin G

    更新日期：2000-02-18 00:00:00

  • Assessing vaccine potency using TCRmimic antibodies.

    abstract：:Dendritic cells (DCs) are highly specialized antigen-presenting cells of the immune system that are efficient at presenting peptide-antigen for the activation of T cells and are often the cell type of choice for vaccine targeting by virtue of high expression levels of MHC and costimulatory molecules. Since the level o...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.02.025

    authors： Neethling FA,Ramakrishna V,Keler T,Buchli R,Woodburn T,Weidanz JA

    更新日期：2008-06-13 00:00:00

  • Enhanced protective efficacy of Borrelia burgdorferi BB0172 derived-peptide based vaccine to control Lyme disease.

    abstract：:Lyme disease (LD) accounts for over 70% of tick-borne disease reported in the United States. The disease in humans is characterized by skin rash, arthritis, cardiac and neurological signs. Vaccination is the most efficient preventive measure that could be taken to reduce the incidence of the LD worldwide; however, at ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.07.092

    authors： Hassan WS,Giaretta PR,Rech R,Ollivault-Shiflett M,Esteve-Gasent MD

    更新日期：2019-09-03 00:00:00

  • Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers.

    abstract：INTRODUCTION:Vaccination of pregnant women protects both women and their newborns against some infectious diseases. Thailand implemented tetanus toxoid (TT) vaccination of pregnant women in 1977, which was replaced by tetanus-diphtheria toxoid (dT) vaccination in 2005. The tetanus-diphtheria-acellular pertussis (Tdap) ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.08.058

    authors： Wanlapakorn N,Maertens K,Thongmee T,Srimuan D,Thatsanathorn T,Van Damme P,Leuridan E,Poovorawan Y

    更新日期：2020-10-14 00:00:00

  • Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China.

    abstract：BACKGROUND:China is the most populous country in the world, with an annual birth cohort of approximately 16 million, requiring an average of 500 million vaccine doses administered annually. In China, over 30 domestic and less than 10 overseas vaccine manufacturers supply over 60 licensed vaccine products, representing ...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2012.11.051

    authors： Guo B,Page A,Wang H,Taylor R,McIntyre P

    更新日期：2013-01-11 00:00:00

  • A therapeutic HIV-1 vaccine reduces markers of systemic immune activation and latent infection in patients under highly active antiretroviral therapy.

    abstract：:HIV infection is characterized by chronic immune activation and the establishment of a pool of latently infected cells. Antiretroviral therapy (ART) can suppress viral load to undetectable levels in peripheral blood by standard measure, however immune activation/chronic inflammation and latent infection persist and af...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.04.015

    authors： Pallikkuth S,Bolivar H,Fletcher MA,Babic DZ,De Armas LR,Gupta S,Termini JM,Arheart KL,Stevenson M,Tung FY,Fischl MA,Pahwa S,Stone GW

    更新日期：2020-06-02 00:00:00

  • Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus.

    abstract：:Recombinant poxviruses are well suited for the development of new vaccine vectors. Our previous data supported the idea that Myxomavirus (MYXV) is efficient at priming antibody responses in sheep. To provide definitive evidence on the potential of MYXV for vaccination against infectious diseases in ruminants, we inves...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.12.108

    authors： Top S,Foucras G,Deplanche M,Rives G,Calvalido J,Comtet L,Bertagnoli S,Meyer G

    更新日期：2012-02-21 00:00:00

  • The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates.

    abstract：:In a previous work we selected montanide ISA720 (M-ISA720) among different adjuvants for the vaccination with a V3 loop based multi-epitope polypeptide TAB9. In this paper we present the evaluation of the toxicity and immunogenicity of this formulation in non-human primates. TAB9 in M-ISA720 was highly immunogenic in ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)00358-2

    authors： Gómez CE,Navea L,Lobaina L,Dubed M,Expósito N,Soto A,Duarte CA

    更新日期：1999-05-04 00:00:00

  • Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches.

    abstract：:Influenza viruses exhibit a fascinating level of antigenic heterogeneity that facilitates re-infection in the human population. The human antibody repertoire also manifests endless capability for variation in the genes that specify the portion of antibody molecules interacting with epitopes. A recent explosion of tech...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.10.124

    authors： Crowe JE Jr

    更新日期：2009-12-30 00:00:00

  • The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap.

    abstract：:Equine influenza is a contagious diseases caused by equine influenza viruses which belong to the orthomyxovirus family. Outbreaks of equine influenza cause severe economic loses to the horse industry and consequently competition horses are required to be regularly vaccinated against equine influenza. Currently availab...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.06.085

    authors： Heldens JG,Pouwels HG,Derks CG,Van de Zande SM,Hoeijmakers MJ

    更新日期：2009-09-04 00:00:00

  • Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits.

    abstract：:Biodegradable nanoparticles coated with proteins represent a promising method for in vivo delivery of vaccines. Here we used a rabbit model to compare quantitatively and qualitatively the antibody responses induced by poly(D,L-lactide) nanoparticles (PLA) and by emulsion adjuvant MF59 using three HIV-1 antigens: p24ga...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.08.060

    authors： Guillon C,Mayol K,Terrat C,Compagnon C,Primard C,Charles MH,Delair T,Munier S,Verrier B

    更新日期：2007-10-23 00:00:00

  • Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group.

    abstract：:A large, randomized, placebo-controlled clinical trial in Italy on two three-component pertussis vaccines, given as DTaP in infancy, one manufactured by SmithKline and Beecham (SB) and one by Chiron Biocine (CB), found each vaccine to be 84% efficacious through the average age of 24 months. The cohort of children enro...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/s0264-410x(98)00040-1

    authors： Salmaso S,Mastrantonio P,Wassilak SG,Giuliano M,Anemona A,Giammanco A,Tozzi AE,Ciofi degli Atti ML,Greco D

    更新日期：1998-08-01 00:00:00

  • Fish soluble Toll-like receptor (TLR)5 amplifies human TLR5 response via physical binding to flagellin.

    abstract：:Fish has a soluble form of TLR5 ortholog (TLR5S), which does not exist in mammals. We identified TLR5S from rainbow trout and named rtTLR5S, which was about 38% homologous to the extracellular domains of human (hu) and mouse TLR5. Adjuvancy of rtTLR5S to flagellin response by human TLR5 (huTLR5) was tested in this stu...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.11.003

    authors： Tsujita T,Ishii A,Tsukada H,Matsumoto M,Che FS,Seya T

    更新日期：2006-03-15 00:00:00

  • Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?

    abstract：:The continued use of oral polio vaccine (OPV) poses a threat to polio virus eradication. Stopping all polio vaccination in the post-certification era is no longer considered to be a practical option. Policy makers agree that OPV use must stop immediately after certification. Therefore, the pragmatic alternative is for...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.02.008

    authors： Khan MM

    更新日期：2008-04-07 00:00:00

  • Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits.

    abstract：:The next-generation human anthrax vaccine developed by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) is based upon purified Bacillus anthracis recombinant protective antigen (rPA) adsorbed to aluminum hydroxide adjuvant (Alhydrogel). In addition to being safe, and effective, it is...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.02.013

    authors： Ribot WJ,Powell BS,Ivins BE,Little SF,Johnson WM,Hoover TA,Norris SL,Adamovicz JJ,Friedlander AM,Andrews GP

    更新日期：2006-04-24 00:00:00

  • Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice.

    abstract：:The carboxyl-terminal region of the merozoite surface protein-1 (MSP1) is a leading candidate for a vaccine against malaria in the erythrocytic stage. In this study, we investigated the utility of interleukin-12 (IL-12) cDNA as an adjuvant for malaria DNA vaccine in a mouse challenge model. We found that co-immunizati...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(02)00665-5

    authors： Sakai T,Hisaeda H,Nakano Y,Zhang M,Takashima M,Ishii K,Maekawa Y,Matsumoto S,Nitta Y,Miyazaki Ji,Yamamoto S,Himeno K

    更新日期：2003-03-28 00:00:00

  • Chapter 8: Screening for cervical cancer in developing countries.

    abstract：:Organised and quality assured cytology-based screening programmes have substantially reduced cervical cancer incidence in many developed countries. However, there are considerable barriers to setting up cytology-based screening programs, particularly in developing countries. This has stimulated the search for novel an...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2006.05.121

    authors： Denny L,Quinn M,Sankaranarayanan R

    更新日期：2006-08-31 00:00:00

  • Surveillance for adverse events after DTwP/Hib vaccination in Brazil: sensitivity and factors associated with reporting.

    abstract：:We estimated the sensitivity, i.e., the proportion of all cases of adverse events following immunization (AEFIs) reported to the Brazilian passive surveillance for adverse events following immunization (PSAEFI) with the diphtheria-tetanus-whole-cell pertussis-Haemophilus influenzae type b (DTwP/Hib) vaccine, as well a...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.02.059

    authors： Monteiro SA,Takano OA,Waldman EA

    更新日期：2010-04-19 00:00:00

  • Combination vaccines in the South African setting.

    abstract：:The number of vaccines available and included as part of the national immunization schedules, has increased significantly over the past few decades. This impacts on patient/parent compliance and creates a challenge for health care providers for implementation of schedules necessitating training and infrastructure impr...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2012.05.001

    authors： Visser A,Hoosen A

    更新日期：2012-09-07 00:00:00

  • Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.

    abstract：BACKGROUND:This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate. METHODS:Eighty subjects were enrolled in playgroups among whom there was at least one infected vaccinee in close contact with a ser...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2005.12.002

    authors： Madhi SA,Cutland C,Zhu Y,Hackell JG,Newman F,Blackburn N,Murphy BR,Belshe RB,Karron RA,Deatly AM,Gruber WC,Bernstein DI,Wright PF

    更新日期：2006-03-20 00:00:00

  • HPV infections among young MSM visiting sexual health centers in the Netherlands: Opportunities for targeted HPV vaccination.

    abstract：INTRODUCTION:In 2009, girls-only HPV16/18 vaccination was introduced in the Netherlands which has achieved 46-61% uptake. Heterosexual men have benefitted from herd protection, but it is unknown whether men who have sex with men (MSM) also benefit from herd effects of the girls-only HPV16/18 vaccination program. Becaus...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.03.002

    authors： Woestenberg PJ,van Benthem BHB,Bogaards JA,King AJ,van der Klis FRM,Pasmans H,Leussink S,van der Sande MAB,Hoebe CJPA,Medical Microbiological Laboratories, the Public Health Services.

    更新日期：2020-04-09 00:00:00

  • Diarrhea hospitalization costs among children 

    abstract：BACKGROUND:Following a recommendation by the World Health Organization, Madagascar introduced rotavirus vaccine in 2014. Though national rotavirus vaccine coverage has remained <80%, rotavirus hospitalizations declined by 78%. Gavi, the Vaccine Alliance, has provided financial support for rotavirus vaccine, however the...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.09.082

    authors： Burnett E,Rahajamanana VL,Raboba JL,Weldegebriel G,Vuo Masembe Y,Mwenda JM,Parashar UD,Tate JE,Robinson AL

    更新日期：2020-11-03 00:00:00

  • Impaired cellular immune response to tetanus toxoid but not to cytomegalovirus in effectively HAART-treated HIV-infected children.

    abstract：:Despite of highly active antiretroviral therapy, the response to vaccines in HIV-infected children is poor and short-lived, probably due to a defect in cellular immune responses. We compared the cellular immune response (assessed in terms of IFN-γ production) to tetanus toxoid and to cytomegalovirus in a series of 13 ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.03.035

    authors： Alsina L,Noguera-Julian A,Fortuny C

    更新日期：2013-05-07 00:00:00

  • Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection.

    abstract：:Binding of antibodies to oligomeric envelope glycoprotein of R5-tropic primary isolates of human immunodeficiency virus type 1 (HIV-1) was studied by flow cytometry using sera from HIV-1 vaccine recipients and clade B and C HIV-1-infected patients, and monoclonal and polyclonal antibodies to neutralizing epitopes of H...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2003.07.013

    authors： Gorse GJ,Patel GB,Arbuckle JA,Belshe RB

    更新日期：2004-01-02 00:00:00

  • Decreasing invasive pneumococcal disease in the elderly: a state-level analysis.

    abstract：:Evidence has accumulated supporting the relationship between the use of 7-valent pneumococcal conjugate vaccine (PCV7) in children and a decline in invasive pneumococcal disease (IPD) in the elderly. We conducted a state-level analysis of vaccination coverage rates among children 19-35 months of age and IPD hospitaliz...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.04.055

    authors： McBean AM,Jung K,Hebert PL

    更新日期：2006-07-07 00:00:00